Brokerages Set Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Target Price at $6.67

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) have earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $6.6667.

Several research firms have issued reports on IPHA. HC Wainwright lifted their price objective on Innate Pharma from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Citigroup upgraded Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Tuesday, August 11th. Finally, UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th.

Institutional Investors Weigh In On Innate Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in Innate Pharma in the fourth quarter worth about $36,000. OLD Mission Capital LLC bought a new stake in Innate Pharma in the fourth quarter valued at about $50,000. Finally, Jane Street Group LLC acquired a new stake in Innate Pharma during the fourth quarter valued at approximately $162,000. Institutional investors own 0.16% of the company’s stock.

Innate Pharma Stock Down 0.5%

Shares of NASDAQ IPHA opened at $1.87 on Friday. Innate Pharma has a 1 year low of $1.17 and a 1 year high of $2.71. The stock’s 50-day simple moving average is $1.97 and its 200-day simple moving average is $1.74.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.